---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-243358"
form_type: "8-K"
ticker: "TKNO"
cik: "0001850902"
company_name: "Alpha Teknova, Inc."
filed_at: "2021-08-11T23:59:59+00:00"
generated_at: "2026-06-29T15:41:25.694890+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alpha Teknova Q2 2021 revenue up 38% to $8.3M; net loss of $2.3M vs prior-year profit

## Summary
- Total revenue $8.3M, +38% YoY; Lab Essentials revenue $6.5M (+46%), Clinical Solutions $1.6M (+32%).
- Gross margin fell to 40.4% from 57.4%; cost of sales included $0.7M one-time reserve for excess Sample Transport inventory.
- Net loss attributable to common stockholders $2.3M ($0.52/share) vs net income of $0.1M ($0.02/share) in Q2 2020.
- Adjusted EBITDA negative $1.5M vs positive $1.2M a year ago; cash position $108M after $99.1M IPO net proceeds.
- Began construction on new GMP facility in Hollister, CA; appointed three new independent directors.

## SEC filing metadata
- accession: 0001193125-21-243358
- form_type: 8-K
- ticker: TKNO
- cik: 0001850902
- company_name: Alpha Teknova, Inc.
- filed_at: 2021-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850902/000119312521243358/0001193125-21-243358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850902/000119312521243358/d192651d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-243358
- JSON: https://secwatch.observer/filing/0001193125-21-243358.json
- Plain text: https://secwatch.observer/filing/0001193125-21-243358.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.